210574-45-1

Basic information

• Product Name: Carbamic acid, 3-cyclohexen-1-yl-, phenylmethyl ester
• CAS NO: 210574-45-1
• Molecular Formula: C14H17NO2
• Molecular Weight: 231.294
• Mol File: 210574-45-1.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: Carbamic acid, 3-cyclohexen-1-yl-, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, 3-cyclohexen-1-yl-, phenylmethyl ester(210574-45-1)
• EPA Substance Registry System: Carbamic acid, 3-cyclohexen-1-yl-, phenylmethyl ester(210574-45-1)

Safety Data

• Hazardous Substances Data: 210574-45-1(Hazardous Substances Data)

Upstream product

• 4771-80-6 1,2,5,6-tetrahydrobenzoic acid 
• 3422-03-5 benzyloxycarbonyl azide 
• 501-53-1 benzyl chloroformate 
• 140-88-5 ethyl acrylate 
• 621-84-1 O-benzyl carbamate 
• 2100-17-6 4-pentenal 
• 100-51-6 benzyl alcohol 
• 4103-88-2 1-isocyano-3-cyclohexene 

Downstream Products

• 1671-86-9 3,6-di(pyridin-2-yl)-1,4-dihydro-1,2,4,5-tetrazine 

Relevant articles and documents

Catalytic Decarboxylative C?N Formation to Generate Alkyl, Alkenyl, and Aryl Amines

Transition-metal-catalyzed sp2 C?N bond formation is a reliable method for the synthesis of aryl amines. Catalytic sp3 C?N formation reactions have been reported occasionally, and methods that can realize both sp2 and sp3 C?N formation are relatively unexplored. Herein, we address this challenge with a method of catalytic decarboxylative C?N formation that proceeds through a cascade carboxylic acid activation, acyl azide formation, Curtius rearrangement and nucleophilic addition reaction. The reaction uses naturally abundant organic carboxylic acids as carbon sources, readily prepared azidoformates as the nitrogen sources, and 4-dimethylaminopyridine (DMAP) and Cu(OAc)2 as catalysts with as low as 0.1 mol % loading, providing protected alkyl, alkenyl and aryl amines in high yields with gaseous N2 and CO2 as the only byproducts. Examples are demonstrated of the late-stage functionalization of natural products and drug molecules, stereospecific synthesis of useful α-chiral alkyl amines, and rapid construction of different ureas and primary amines.

COMBINATION THERAPIES WITH IRE1 SMALL MOLECULE INHIBITORS

Provided herein are methods of using IRE1 small molecule inhibitors in combination therapies for treating cancer in a subject. The IRE1 small molecule inhibitors described herein may be used in combination therapies for treating solid and hematologic cancers.

IRE1 SMALL MOLECULE INHIBITORS

Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.